A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...

Studies suggest that semaglutide reduces heart attack and stroke and may curb addiction and more. Scientists reflect on the future of GLP-1 drugs beyond weight loss.

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and acceptably safe for the treatment of type 2 diabetes and obesity, leading to ...

Biotech leader says additional research into existing medications, drug classes, and mechanisms of action can bring forth ...

A bipartisan group of senators are filing a bill that would force health insurers or PBMs to divest their pharmacy businesses ...

HHS has extended liability protections for COVID-19 vaccines, treatments and diagnostic tests under the Public Readiness and Emergency Preparedness Act through Dec. 31, 2029.

Eli Lilly will launch studies to investigate whether its weight loss medications can help control addictive behaviors such as smoking and alcohol and drug abuse, CEO Dave Ricks revealed in a Dec. 10 ...